ASP Isotopes Inc. (ASPI)
$2.28-6.56%Close
SELLCRISIS · day 24
Key stats
Short interest · FINRA settlement 2026-09-30
52-week IV59.1%–245.1%
- Market cap
- $189M
- Beta
- 3.70
- P/E (TTM)
- -1.73
- IV-%ile
- 81
- IV ATM
- 138.2%
- Short % float
- 39.42%
- Days to cover
- 5.3
- SI change
- +1.5%
- 1W
- -20.00%
- 1M
- -28.53%
- vs SPY 1W
- -19.86%
- vs SPY 1M
- -31.03%
Industry peers
FMP comparable companies · ranked by market cap
- SCLSELLStepan Co$1.4BBEARQ 15$61.04+1.99%
- IAUXSELLi-80 Gold Corp$1.3BCRISISQ -5$1.54-2.53%
- ODCSELLOil-Dri Corporation of America$1.2BRECOVERYQ 22$84.37+2.40%
- GPREBUYGreen Plains Inc.$1.1BRECOVERYQ 6$15.06+6.71%
- CMPSELLCompass Minerals International, Inc.$968MRECOVERYQ 10$23.08+1.49%
- GSMSELLFerroglobe PLC$789MRECOVERYQ 8$4.19+2.20%
- WLKPSELLWestlake Chemical Partners LP$755MBEARQ 12$21.41+0.09%
- BAKBUYBraskem S.A.$725MRECOVERYQ 10$1.82+5.06%
- TROXSELLTronox Holdings plc$603MCRISISQ 1$3.78+0.57%
- UAMYSELLUnited States Antimony Corporation$551MCRISISQ 15$3.72-6.55%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 6
- VALUE
- 5
- GROWTH
- 9
- GARP
- 1
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-38.1%
REV YoY-
ROE-63.5%
EPS YoY-
ROA-23.1%
GROSS18
OP-312
NET-428
[VALUATION]
P/E TTM-1.73
P/E FWD-
SECTOR PE25.24
INDUSTRY PE28.99
P/B1.06
P/FCF-
EV/EBITDA-2.61
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E101.86
ALTMAN Z-
CURR RATIO3.87
ND/EBITDA-
BETA3.70
Company news
FAQ
- What is LOPJLB’s current signal on ASPI?
- LOPJLB’s latest quantitative signal on ASP Isotopes Inc. Common Stock (ASPI) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is ASPI in?
- ASP Isotopes Inc. Common Stock (ASPI) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does ASP Isotopes Inc. Common Stock (ASPI) do?
- ASP Isotopes Inc. is an emerging advanced materials company, currently in its pre-commercial stage. This firm is dedicated to the comprehensive management of isotopes, encompassing their creation, dissemination, promotion, and eventual sale. The company's developmental portfolio includes Molybdenum-100, a non-radioactive isotope designed for medical applications, alongside Carbon-14 and Silicon…